Cure My Disease

Don't miss your cure!

 Log in / Sign up

Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma

NCT ID NCT07027748

Recruiting now Disease control Sponsor: Steven DuBois, MD Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 1 trial tests whether giving the immunotherapy naxitamab more slowly, alongside standard chemotherapies irinotecan and temozolomide plus sargramostim, can reduce side effects in children with relapsed or refractory neuroblastoma. The study enrolls about 18 patients whose high-risk neuroblastoma has returned or not responded to prior treatment. The main goal is to find a safe infusion duration for naxitamab that causes fewer severe reactions, especially pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of naxitamab (an immunotherapy), irinotecan, temozolomide, and sargramostim
What this could lead to
If successful, this could lead to a better-tolerated treatment option for children with relapsed or refractory neuroblastoma.
What could go wrong
This is a small, early-phase feasibility study, so the approach may not prove effective or safer in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA NEUROBLASTOMA RECURRENT REFRACTORY NEUROBLASTOMA RELAPSED NEUROBLASTOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.